Deep Knowledge Group Swiss Longevity Events in November 2021
From 21-26 November 2021, several Deep Knowledge Group Partners and Senior Executives visited Switzerland (Geneva, Zurich, and Basel) to host several invitation-only Longevity Finance and Investment events and to engage key Swiss stakeholders (government officials and industry professionals) on the prospects for transforming Switzerland into the world’s leading full-scope Longevity Finance, Industry, Biomedicine, and Policy Hub (Swiss Longevity Valley).
The Deep Knowledge Group team in attendance for the events included:
Deep Knowledge Group General Partner, Dmitry Kaminskiy;
Managing Partner Stefan Hascoet (who also leads Deep Knowledge Ventures Swiss, Deep Knowledge financial branch, located in Geneva);
Managing Partner, Dr. Sanja Baumann-Tomovska (a Basel-based precision medicine professional with 10+ years experience as a Department Head at Roche, Novartis & Abbott Life Sciences);
Director of Structured Products, Remus Stanescu (who also leads Deep Knowledge Group’s UK-based financial branch, Longevity Financial Advisors, located in London);
Partner and Director of Deep Knowledge Analytics and GovTech Analytics, Alex Cresniov;
Deputy General Partner, Head of Investment Analytics, Ihor Kendiukhov; and
Vice President of Business Development and Investor Relations, Anastasia Lit.
Deep Knowledge Group has been prioritizing its activities in Switzerland at the intersection of Longevity Finance, Investment, Industrialization and Policy for many years now to analyze the country's unique strengths and synergies in the spheres of Biomedicine, Precision Medicine, International Policy, Financial Industry, and Advanced AI-Empowered InvestTech Solutions to constitute an ideal foundation that could be leveraged to develop Switzerland into a world-leading full-scope Longevity Valley.
Investing in Longevity Event in Geneva, Switzerland
Deep Knowledge Group has been prioritizing its activities in Switzerland at the intersection of Longevity Finance, Investment, Industrialization, and Policy for many years now. The primary focus of this initiative is to analyze the country's unique strengths and synergies in Biomedicine, Precision Medicine, International Policy, Financial Industry, and Advanced AI-Empowered InvestTech solutions to constitute an ideal foundation that could be leveraged to turn Switzerland into a world-leading full-scope Longevity Valley.
Investing in Longevity Event in Geneva, Switzerland
On 23 November 2021, Deep Knowledge Group hosted an invitation-only Longevity Event in Geneva: INVESTING IN LONGEVITY.
The event covered several important topics, including:
Investing into the Largest Wealth Creation Opportunity of The Decade;
Private Equity, Venture Capital, Public Markets;
De-Risking and Optimization of Investments;
Practical Human Longevity; and
Hype vs. Reality.
Deep Knowledge Group General Partner Dmitry Kaminskiy delivered a presentation entitled Longevity Industry Overview 2021-2022 and Longevity Investments De-Risking/Longevity Finance. He was joined by Deep Knowledge Group Managing Partner Stefan Hascoet, who gave a presentation on Private Equity & Venture, Longevity Assets, and Financial Products. Stefan leads Deep Knowledge Ventures Swiss, a Geneva-based financial arm of Deep Knowledge Group devoted to the development of structured financial products and derivatives in Switzerland. He is also responsible for conducting various financial and investment activities in the DeepTech industries.
During the event, the Deep Knowledge Group team witnessed a strong interest in the Longevity Industry from many investors, financial executives, and industry professionals with whom we discussed the future perspectives of the industry.
Dmitry Kaminskiy also delivered a presentation of his series of published and upcoming Longevity Books, including:
Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History;
Longevity Financial Industry: Health as the New Wealth;
Longevity FinTech, WealthTech, InvestTech, InsurTech, AgeTech, and the Coming Rise of Longevity Banks, Investment Banks, Stock Exchanges, ETFs, Indices, and Novel Financial Instruments and Derivatives; and
Longevity Industry 2.0: DeepTech Engineering the Accelerated Trajectory of Human Longevity (The Blueprint and Pathway from Longevity Industry 1.0 to 2.0).
But with major emphasis on his newest book, Biomarkers of Human Longevity: Data Science for Accelerating Aging Research and R&D and The Critical Catalyst for Practical Human Longevity, Tangible Investment Decision Making and De-Risking.
Investing in Longevity Event in Zurich, Switzerland
The following day, on 24 November 2021, a parallel INVESTING IN LONGEVITY private event was hosted by Deep Knowledge Group in Zurich, Switzerland.
Deep Knowledge Group General Partner Dmitry Kaminskiy delivered a presentation entitled Longevity Industry Overview 2021-2022 and Longevity Investments De-Risking/Longevity Finance. It was followed by a talk by Remus Stanescu, Director of Structured Products at Deep Knowledge Group’s UK-based financial branch, Longevity Financial Advisors, which provided an Overview of Deep Knowledge Group Financial Activities.
The event also featured early discussions on Deep Knowledge Group’s dedicated biomarkers subsidiary, Quant Biomarkers company (data-driven biotechnology, precision medicine, and financial services company focused on applications of Longevity Biomarkers across numerous sectors, including InsurTech and InvestTech).
Longevity Meets Basel
On 25 November 2021, in Basel, Switzerland, several Deep Knowledge Group Partners, and senior executives attended the Longevity Meets Basel — a conference by the prestigious Weizman Institute of Science (WYEN), hosted by WYEN Board Member Dr. Sanja Baumann-Tomovska.
During the conference, Deep Knowledge Group General Partner Dmitry Kaminskiy delivered a keynote presentation entitled "Biomarkers of Human Longevity as the Critical Catalyst for Tangible Investment Decision-Making and De-Risking."
Dmitry Kaminskiy also chaired a Panel Discussion (Aging: The Longevity Dividend), featuring several Longevity-investment, policy, and biomedicine firms, including:
Joanna Bensz (Co-Founder and CEO, Longevity Center; CEO, International Institute of Longevity);
Leo Grunstein (Founder and CEO of Spiden AG, Chairman of Venture Builder LG Capital AG);
Dr. Yaron Daniely (Partner, Amoon);
Dr. Tobias Reichmuth (Founding Partner, Maximon);
Garri Zmudze (Founding Partner, Longe-VC); and
Dr. Matthias Steger (Co-Founder and CEO, Rejuveron Life Sciences).
Pictured below is Dmitry Kaminsky discussing his newest book, Biomarkers of Human Longevity: Data Science for Accelerating Aging Research and R&D and The Critical Catalyst for Practical Human Longevity, Tangible Investment Decision Making and De-Risking, with Prince Michael Von Liechtenstein, a member of the House of Lichtenstein and an heir to the Liechtensteiner throne, as well as Co-Founder of the International Institute of Longevity and Longevity Center, Chairman of the European Center of Austrian Economics Foundation Vaduz, Executive Chairman of Industrie- und Finanzkontor Ets. Vaduz (a leading trust company specializing in long-term and multi-generational preservation of wealth), and Founder and Chairman of Geopolitical Intelligence Services AG Vaduz.
Longevity and DeepTech in Switzerland: What’s Next?
While this is only the second dedicated set of Deep Knowledge Group Longevity Events in Switzerland, it will not be the last. The Group has been prioritizing Switzerland as one of the most prospective hubs for its Longevity and DeepTech activities, especially at the intersections of precision medicine, investment, financial industry, InvestTech, and Policy for many years now.
The Group decided in 2019 to headquarter its Swiss-based financial arm, Deep Knowledge Ventures Swiss, in Geneva to leverage the region’s unique financial industry strengths and reputation. Deep Knowledge Ventures Swiss is devoted to the development of structured financial products and derivatives in Switzerland. It is also responsible for conducting various financial and investment activities in the DeepTech industries.
Meanwhile, the Group also decided to launch its dedicated Longevity Biomarkers company, Quant Biomarkers, in Basel, Switzerland (with branches in the United Kingdom, Germany, and Ukraine) under the directorship of Wyen Board Member Dr. Sanja Baumann-Tomovska (a Basel-based precision medicine professional with 10+ years experience as a department head at Roche, Novartis & Abbott Life Sciences).
Quant Biomarkers company is a data-driven financial and biotechnology company, specializing in quantitative assessment of human biomarkers; development of biomarker panels and biological age metrics; their application for investment de-risking, insurance, and hedging objectives; development of structured financial products; and analytics linked to human biomarkers and biological age. The main goal of the company is to introduce biomarkers-driven longevity risks mitigation for a broad group of financial and healthcare-related entities.
One of the primary goals of the company for 2022-2023 is to introduce biomarkers-driven Longevity risk mitigation for a broad group of healthcare-related entities, and the development of a specialized platform to aggregate, integrate, and synthesize the expertise, products, and services of other leading biomarker companies and R&D centers into one unified platform using cutting edge next-generation AI, deep learning and reinforcement learning technologies.
These developments will further fuel the parallel development of data-driven InvestTech solutions for due diligence, novel financial products for the next generation of InsurTech (healthcare insurance focused on tangible Practical Human Longevity), and the most sophisticated and validated market-ready technologies for Precision Medicine and Longevity clinics.
Deep Knowledge Ventures Swiss and Quant Biomarkers will also lead the development of the Longevity International Association and Swiss Longevity Valley as major non-profit forums for sustainable development of Longevity and Aging Research to identify ways of raising the profile of the sector in Europe and to incentivize major stakeholders: business, science, governments, clinical centers, insurers, and banking institutions.